Researchers studied the effect of apremilast on body weight and composition, glucose homeostasis, lipid profiles, and vascular function in psoriatic disease.
Higher body mass index (BMI) seems to be associated with an increased risk for developing psoriasis.
Individuals with co-occurrence of vitiligo and psoriasis have an increased risk for autoimmunity and family history of psoriasis.
Psoriasis and psoriatic arthritis have been associated with the underreporting and undertreatment of pain. To provide adequate care and management of pain in psoriatic disease, a multidisciplinary approach is required.
In this episode, dermatologist Joel Gelfand, MD, and rheumatologist Alexis Ogdie, MD, provide deeper insight into the overlap and transition of care between patients with psoriasis and PsA.
Greater skin clearance among psoriasis patients is associated with greater improvements in quality of life.
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
The relationships between musculoskeletal symptoms and the development of psoriatic arthritis in patients with psoriasis was explored.
Using a network meta-analysis, researchers compared guselkumab with targeted therapies for psoriatic arthritis for safety and joint and skin efficacy.
The prevalence and predictors of stigmatizing attitudes that patients with psoriasis anticipate and experience was investigated.
